Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

[125I‐His9]‐Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up‐regulation of receptors with atherosclerosis

Open access
Katugampola, Sidath D, Pallikaros, Zakos, Davenport, Anthony P · 2001 · British Journal of Pharmacology

Abstract

Ghrelin is the recently identified endogenous ligand for the cloned growth hormone secretagogue receptor (GHS‐R). We have characterized for the first time the binding of human [125 I‐His9]‐ghrelin to normal human and rat tissue and demonstrated expression of this ‘orphan’ receptor that has previously been predicted to exist from mRNA. Furthermore, we have discovered that [125 I‐His9]‐ghrelin density is significantly increased in atherosclerosis. [125 I‐His9]‐Ghrelin bound to non‐diseased human heart (left ventricle) with an association rate constant (k obs) of 0.16±0.004 min−1, a dissociation rate constant of 0.068±0.0005 min−1 (kinetically derived KD of 0.1 n M; n=5 individuals±s.e.mean), a KD of 0.43±0.08 n M and B max of 7.8±0.9 fmol mg−1 protein (n=6 individual±s.e.mean). Specific [125 I‐His9]‐ghrelin binding was to the human vasculature including aorta, coronary, pulmonary, arcuate arteries in the kidney and saphenous veins. In rat tissues, binding sites were also localized to the vasculature in peripheral tissues as well as the granular layer of the cerebellum in the CNS. [125 I‐His9]‐Ghrelin binding was significantly up‐regulated (3 – 4 fold) in both atherosclerotic coronary arteries and saphenous vein grafts with advanced intimal thickening, compared with normal vessels (P<0.05). Our results suggest that the native receptor for [125 I‐His9]‐ghrelin may be widely distributed in the human cardiovascular system. Furthermore, changes in the density of this proposed ghrelin receptor implicates this new transmitter system in the development of atherosclerosis and may therefore represent a novel therapeutic target in the treatment of cardiovascular disease. British Journal of Pharmacology (2001) 134, 143–149; doi:10.1038/sj.bjp.0704228

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0704228

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 191

Metadata

Authors
Katugampola, S. D., Pallikaros, Z., & Davenport, A. P.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2001-09
Volume
134
Issue
1
Pages
143-149
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2031481579
Cited by
191
References
2
FWCI
3.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: [125I‐His9]‐Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up‐regulation of receptors with atherosclerosis. https://app.cochat.ai/papers/10.1038/sj.bjp.0704228
The paper
Katugampola, S. D., Pallikaros, Z., & Davenport, A. P. (2001). [125I‐His9]‐Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up‐regulation of receptors with atherosclerosis. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0704228

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.